Patents by Inventor Takaaki Inaba

Takaaki Inaba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230190766
    Abstract: The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (?)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.
    Type: Application
    Filed: August 3, 2021
    Publication date: June 22, 2023
    Inventors: Takaaki INABA, Masatomo KATO
  • Patent number: 11642350
    Abstract: The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: May 9, 2023
    Assignees: Singapore Health Services PTE LTD, Santen Pharmaceutical Co., Ltd.
    Inventors: Tiang Hwee Donald Tan, Roger Wilmer Beuerman, Seang-Mei Saw, Aradhana Upadhyay, Masatomo Kato, Takaaki Inaba
  • Publication number: 20200147098
    Abstract: The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.
    Type: Application
    Filed: March 22, 2018
    Publication date: May 14, 2020
    Inventors: Tiang Hwee Donald TAN, Roger Wilmer BEUERMAN, Seang-Mei SAW, Aradhana UPADHYAY, Masatomo KATO, Takaaki INABA
  • Patent number: 8193237
    Abstract: Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKK? and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKK?. In the formula, R1 represents a hydrogen atom, a lower alkyl group, an aryl group, a hydroxy group, or the like; R2 represents a halogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or the like; and m represents 0, 1, 2, or the like.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: June 5, 2012
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Enomoto, Kenji Kawashima, Kazuhiro Kudou, Minoru Yamamoto, Masaaki Murai, Takaaki Inaba, Noriko Ishizaka
  • Patent number: 7977371
    Abstract: Objects of the present invention are to study on the synthesis of a novel pyrrole derivative having a ureido group and an aminocarbonyl group as substituents or a salt thereof, to find a pharmacological effect of the derivative or a salt thereof, and to find a medicinal agent which has a prophylactic and/or therapeutic effect on a retinal disease or the like through oral administration. A compound represented by the general formula (1) or a salt thereof has an inhibitory activity against the production of interleukin-6 and/or an inhibitory effect on choroidal neovascularization, and is therefore useful as a prophylactic and/or therapeutic agent for a disease associated with interleukin-6, an ocular inflammatory disease and/or a retinal disease.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: July 12, 2011
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Kenji Kawashima, Hiroshi Enomoto, Noriko Ishizaka, Minoru Yamamoto, Kazuhiro Kudou, Masaaki Murai, Takaaki Inaba, Kazuyoshi Okamoto
  • Publication number: 20100099675
    Abstract: Objects of the present invention are to study on the synthesis of a novel pyrrole derivative having a ureido group and an aminocarbonyl group as substituents or a salt thereof, to find a pharmacological effect of the derivative or a salt thereof, and to find a medicinal agent which has a prophylactic and/or therapeutic effect on a retinal disease or the like through oral administration. A compound represented by the general formula (1) or a salt thereof has an inhibitory activity against the production of interleukin-6 and/or an inhibitory effect on choroidal neovascularization, and is therefore useful as a prophylactic and/or therapeutic agent for a disease associated with interleukin-6, an ocular inflammatory disease and/or a retinal disease.
    Type: Application
    Filed: February 26, 2008
    Publication date: April 22, 2010
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji Kawashima, Hiroshi Enomoto, Noriko Ishizaka, Minoru Yamamoto, Kazuhiro Kudou, Masaaki Murai, Takaaki Inaba, Kazuyoshi Okamoto
  • Publication number: 20100041628
    Abstract: Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKK? and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKK?. In the formula, R1 represents a hydrogen atom, a lower alkyl group, an aryl group, a hydroxy group, or the like; R2 represents a halogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or the like; and m represents 0, 1, 2, or the like.
    Type: Application
    Filed: January 15, 2008
    Publication date: February 18, 2010
    Inventors: Hiroshi Enomoto, Kenji Kawashima, Kazuhiro Kudou, Minoru Yamamoto, Masaaki Murai, Takaaki Inaba, Noriko Ishizaka
  • Patent number: 7544703
    Abstract: A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R1 and R2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R3 and R4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R5, etc.; R5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents —CO—, —COO—, —CONR6—, —SO2—, etc.; R6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: June 9, 2009
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Takahiro Honda, Hisashi Tajima, Kenji Kawashima, Kazuyoshi Okamoto, Minoru Yamamoto, Takaaki Inaba, Yuriko Takeno
  • Publication number: 20070149574
    Abstract: A novel cyclic compound having a 4-pyridylalkylthio group having an (un)substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R1 and R2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R3 and R4 each represents H, (substituted) alkyl, (substituted) cycloalkyl, -Z-R5, etc.; R5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents —CO—, —COO—, —CONR6—, —SO2—, etc.; R6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.
    Type: Application
    Filed: February 17, 2005
    Publication date: June 28, 2007
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro Honda, Hisashi Tajima, Kenji Kawashima, Kazuyoshi Okamoto, Minoru Yamamoto, Takaaki Inaba, Yuriko Takeno